Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | CA9 | Q16790 | 1/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8248683 | 0.89 | ALDH1A1 (0.65) | CA2CYP19A1MEN1KMT2ALMNA | |
| SCHEMBL16431026 | 0.86 | PGR (0.64) | CA2CYP19A1MEN1KMT2ACA1 | |
| SCHEMBL31441925 | 0.82 | CA2 (0.68) | CA2CA12CA9CYP19A1MEN1 | |
| SCHEMBL4948723 | 0.82 | HTR6 (0.72) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL2243550 | 0.82 | CA2 (0.68) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL11438518 | 0.82 | CA2 (0.68) | CA2CA12CA9MEN1KMT2A | |
| SCHEMBL7808167 | 0.82 | CA2 (0.68) | CA2CA12CA9CYP19A1MEN1 | |
| SCHEMBL18739152 | 0.82 | CA2 (0.68) | CA2CA12CA9CYP19A1MEN1 | |
| SCHEMBL3615295 | 0.82 | VCAM1 (0.59) | CYP19A1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5230151 | 0.81 | CES1 (0.73) | CA2CA12CA9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| CN-117396474-A | Plasma kallikrein inhibitors | 武田药品工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11236044-B2 | Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210147348-A1 | SELECTIVE INHIBITORS OF 12(S)- LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-05-20 | — | — | US | disclosed |
| CN-112566898-A | Selective inhibitors of 12(S) -lipoxygenase (12-LOX) and methods of use thereof | 密歇根大学董事会 | 2021-03-26 | — | — | CN | disclosed |
| EP-3781548-A1 | SELECTIVE INHIBITORS OF 12(S)-LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME | The Regents Of The University Of Michigan (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019204375-A1 | SELECTIVE INHIBITORS OF 12(S)-LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11236044-B2 | Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same | ALOX12, LOX, ALOX15 | CA2 3935/4885CA12 3310/4885CA9 3464/4885 |
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | CA2 2915/4885CA12 1813/4885CA9 1004/4885 |
| US-20210147348-A1 | SELECTIVE INHIBITORS OF 12(S)- LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME | ALOX12, LOX, ALOX15 | CA2 3935/4885CA12 3310/4885CA9 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.